Low testosterone levels have been associated with coronary heart disease (CHD) morbidity and mortality in men, but the influence of hormones in postmenopausal women is unclear. This meta-analysis aimed to examine whether there is an association between endogenous sex hormones and CHD risk in postmenopausal women.
Methods
A systematic search of the PubMed and EMBASE databases from 1966 to 30 November 2016 was performed for prospective studies that reported an association between endogenous sex hormones and CHD in postmenopausal women. Summary relative risks (RRs) and 95% confidence intervals (CIs) were combined by using a random-effects model.
Results
A total of 13 publications (12 studies, including six prospective cohort and six nested case–control studies) were included. The summary RRs for CHD were 1.01 (95% CI 0.77–1.31) comparing the highest versus lowest tertile of total testosterone, with evidence of high heterogeneity (I2 = 80.7%). In subgroup and meta-regression analyses, none of the variables were identified as contributing to significant heterogeneity. Based on a comparison of the highest versus lowest tertile models, the summary RRs (95% CIs) for CHD were 0.88 (0.63–1.23, I2 = 48.7%) for free testosterone, 1.16 (0.82–1.63, I2 = 47.8%) for estradiol, 0.98 (0.90–1.07, I2 = 3.2%) for sex hormone-binding globulin and 1.19 (0.89–1.58, I2 = 0) for dehydroepiandrosterone.
Conclusion
There is limited evidence to suggest that endogenous levels of sex hormones are not significantly associated with CHD risk in postmenopausal women.
LozanoRNaghaviMForemanK. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet2013; 380: 2095–2128.
2.
SharmaROniOAGuptaK. Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. Eur Heart J2015; 36: 2706–2715.
3.
ShoresMMBiggsMLArnoldAM. Testosterone, dihydrotestosterone, and incident cardiovascular disease and mortality in the cardiovascular health study. J Clin Endocrinol Metab2014; 99: 2061–2068.
4.
RuigeJBMahmoudAMDe BacquerD. Endogenous testosterone and cardiovascular disease in healthy men: a meta-analysis. Heart2011; 97: 870–5.
5.
AraujoABDixonJMSuarezEA. Clinical review: Endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab2011; 96: 3007–3019.
6.
DakaBLangerRDLarssonCA. Low concentrations of serum testosterone predict acute myocardial infarction in men with type 2 diabetes mellitus. BMC Endocr Disord2015; 15: 35–35.
7.
Scarabin-CarreVCanonicoMBrailly-TabardS. High level of plasma estradiol as a new predictor of ischemic arterial disease in older postmenopausal women: the three-city cohort study. J Am Heart Assoc2012; 1: e001388–e001388.
8.
WehrEPilzSBoehmBO. Low free testosterone levels are associated with all-cause and cardiovascular mortality in postmenopausal diabetic women. Diabetes Care2011; 34: 1771–1777.
9.
SieversCKlotscheJPieperL. Low testosterone levels predict all-cause mortality and cardiovascular events in women: a prospective cohort study in German primary care patients. Eur J Endocrinol2010; 163: 699–708.
10.
NaessenTSjogrenUBergquistJ. Endogenous steroids measured by high-specificity liquid chromatography-tandem mass spectrometry and prevalent cardiovascular disease in 70-year-old men and women. J Clin Endocrinol Metab2010; 95: 1889–1897.
11.
LaughlinGAGoodellVBarrett-ConnorE. Extremes of endogenous testosterone are associated with increased risk of incident coronary events in older women. J Clin Endocrinol Metab2010; 95: 740–747.
12.
PatelSMRatcliffeSJReillyMP. Higher serum testosterone concentration in older women is associated with insulin resistance, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab2009; 94: 4776–4784.
13.
RexrodeKMMansonJELeeIM. Sex hormone levels and risk of cardiovascular events in postmenopausal women. Circulation2003; 108: 1688–1693.
14.
HaffnerSMMossSEKleinBE. Sex hormones and DHEA-SO4 in relation to ischemic heart disease mortality in diabetic subjects. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Diabetes Care1996; 19: 1045–1050.
15.
Barrett-ConnorEGoodman-GruenD. Prospective study of endogenous sex hormones and fatal cardiovascular disease in postmenopausal women. BMJ1995; 311: 1193–1196.
16.
ChenYZeleniuch-JacquotteAArslanAA. Endogenous hormones and coronary heart disease in postmenopausal women. Atherosclerosis2011; 216: 414–419.
17.
BennMVossSSHolmegardHN. Extreme concentrations of endogenous sex hormones, ischemic heart disease, and death in women. Arterioscler Thromb Vasc Biol2015; 35: 471–477.
18.
PageJHMaJRexrodeKM. Plasma dehydroepiandrosterone and risk of myocardial infarction in women. Clin Chem2008; 54: 1190–1196.
19.
DingELSongYMalikVS. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA2006; 295: 1288–1299.
20.
ShawLJBairey MerzCNAzzizR. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health – National Heart, Lung, and Blood Institute sponsored Women’s Ischemia Syndrome Evaluation. J Clin Endocrinol Metab2008; 93: 1276–1284.
21.
BerniniGPSgroMMorettiA. Endogenous androgens and carotid intimal-medial thickness in women. J Clin Endocrinol Metab1999; 84: 2008–2012.
22.
AdamsMRKaplanJRManuckSB. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. Arteriosclerosis1990; 10: 1051–1057.
23.
GrodsteinFStampferMJMansonJE. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med1996; 335: 453–461.
24.
MudaliSDobsASDingJ. Endogenous postmenopausal hormones and serum lipids: the atherosclerosis risk in communities study. J Clin Endocrinol Metab2005; 90: 1202–1209.
25.
BagliettoLEnglishDRHopperJL. Circulating steroid hormone concentrations in postmenopausal women in relation to body size and composition. Breast Cancer Res Treat2009; 115: 171–179.
26.
DingELSongYMansonJE. Plasma sex steroid hormones and risk of developing type 2 diabetes in women: a prospective study. Diabetologia2007; 50: 2076–2084.
27.
ShlipakMGChaputLAVittinghoffE. Lipid changes on hormone therapy and coronary heart disease events in the Heart and Estrogen/progestin Replacement Study (HERS). Am Heart J2003; 146: 870–875.
28.
HeissGWallaceRAndersonGL. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008; 299: 1036–1045.
29.
BoardmanHMHartleyLEisingaA. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev2015. CD002229.
30.
StroupDFBerlinJAMortonSC. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA2000; 283: 2008–2012.
DaneshJCollinsRApplebyP. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA1998; 279: 1477–1482.
33.
HigginsJPThompsonSGDeeksJJ. Measuring inconsistency in meta-analyses. BMJ2003; 327: 557–560.
34.
BeggCBMazumdarM. Operating characteristics of a rank correlation test for publication bias. Biometrics1994; 50: 1088–1101.
35.
EggerMDavey SmithGSchneiderM. Bias in meta-analysis detected by a simple, graphical test. BMJ1997; 315: 629–634.
36.
DavisSRMoreauMKrollR. Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med2008; 359: 2005–2017.
37.
WhiteWBGradyDGiudiceLC. A cardiovascular safety study of LibiGel (testosterone gel) in postmenopausal women with elevated cardiovascular risk and hypoactive sexual desire disorder. Am Heart J2012; 163: 27–32.
38.
RosnerWAuchusRJAzzizR. Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab2007; 92: 405–413.
39.
RozenbergSBossonDPeretzA. Serum levels of gonadotrophins and steroid hormones in the post-menopause and later life. Maturitas1988; 10: 215–224.
40.
El KhoudarySRShieldsKJJanssenI. Cardiovascular fat, menopause, and sex hormones in women: the SWAN Cardiovascular Fat Ancillary Study. J Clin Endocrinol Metab2015; 100: 3304–3312.
41.
DerbyCACrawfordSLPasternakRC. Lipid changes during the menopause transition in relation to age and weight: the Study of Women’s Health Across the Nation. Am J Epidemiol2009; 169: 1352–1361.
42.
ShiZAraujoABMartinS. Longitudinal changes in testosterone over five years in community-dwelling men. J Clin Endocrinol Metab2013; 98: 3289–3297.
43.
BrambillaDJMatsumotoAMAraujoAB. The effect of diurnal variation on clinical measurement of serum testosterone and other sex hormone levels in men. J Clin Endocrinol Metab2009; 94: 907–913.
44.
HankinsonSEMansonJESpiegelmanD. Reproducibility of plasma hormone levels in postmenopausal women over a 2–3-year period. Cancer Epidemiol Biomarkers Prev1995; 4: 649–654.
45.
KotsopoulosJTworogerSSCamposH. Reproducibility of plasma and urine biomarkers among premenopausal and postmenopausal women from the Nurses’ Health Studies. Cancer Epidemiol Biomarkers Prev2010; 19: 938–946.
46.
ZhaoJLeungJYLinSL. Cigarette smoking and testosterone in men and women: A systematic review and meta-analysis of observational studies. Prev Med2016; 85: 1–10.
47.
SowersMFBeebeJLMcConnellD. Testosterone concentrations in women aged 25–50 years: associations with lifestyle, body composition, and ovarian status. Am J Epidemiol2001; 153: 256–264.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
